Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.23 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tg100-801, e-7090, nintedanib esylate +23 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 23 Parkinson's papers of 6,025 | 0.58 |
| pathways Reactome | 22 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 1820
Sealed predictions
- FGFR1 in dopamine neurons, braak+0.14 (p 0.714) → -0.35 (p 0.349)receipt 1826
Swarm cases
receipt 1826: FGFR1 in dopamine neurons, braak
- power
- full sample -0.07 (p 0.781, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.908, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.24 (p 0.332, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.06, sign flips 3; without severely affected donors -0.07 (p 0.781, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FGFR1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts